Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170819 | 0.82 | — | — | |
| SCHEMBL27983255 | 0.80 | — | — | |
| SCHEMBL2009396 | 0.80 | — | — | |
| SCHEMBL954218 | 0.80 | — | — | |
| SCHEMBL10715836 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL26978407 | 0.80 | KMT2A (0.44) | KMT2AHDAC8PIK3CDIDO1TDO2 | |
| SCHEMBL299024 | 0.80 | — | — | |
| Water SCHEMBL23727754 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL28317604 | 0.78 | KMT2A (0.43) | KMT2AHDAC8PIK3CDIDO1TDO2 | |
| SCHEMBL27926586 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103998042-A | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG | 2014-08-20 | — | — | CN | claimed |
| CN-102971317-A | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG | 2013-03-13 | — | — | CN | claimed |
| EP-3048156-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | cynora GmbH (DE) | 2016-07-27 | — | — | EP | disclosed |
| EP-3048155-A1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC COMPONENTS | cynora GmbH (DE) | 2016-07-27 | — | — | EP | disclosed |
| CN-104086565-A | FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB | 2014-10-08 | — | — | CN | disclosed |
| CN-103998042-A | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG | 2014-08-20 | — | — | CN | disclosed |
| CN-102971317-A | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG | 2013-03-13 | — | — | CN | disclosed |
| CN-102245605-A | Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections | ASTRAZENECA AB | 2011-11-16 | — | — | CN | disclosed |
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
| US-5631264-A | NEUROLOGICAL DISORDERS | SANOFI WINTHROP, INC. (US) | 1997-05-20 | — | — | US | disclosed |
| US-5604224-A | NEURODEGENERATIVE DISORDERS | STERLING WINTHROP INC. (US) | 1997-02-18 | — | — | US | disclosed |
| US-5569655-A | Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1996-10-29 | — | — | US | disclosed |
| US-5554620-A | Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof | STERLING WINTHROP INC. (US) | 1996-09-10 | — | — | US | disclosed |
| EP-0656359-A1 | Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts and compositionsand methods of use thereof | STERLING WINTHROP INC. (US) | 1995-06-07 | — | — | EP | disclosed |
| EP-0647641-A1 | Substituted heterocyclylisoquinolinium salts and compositions and methods of usethereof | STERLING WINTHROP INC. (US) | 1995-04-12 | — | — | EP | disclosed |
| EP-0623130-A1 | ANTIBACTERIAL 1-NORMON-2-YL THIAZOLYL KETONES | SMITHKLINE BEECHAM PLC (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993015072-A1 | ANTIBACTERIAL 1-NORMON-2-YL THIAZOLYL KETONES | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | KMT2A 1452/4885HDAC8 1051/4885PIK3CD 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.